Leopold Bertea, a cell and gene therapy expert, has joined Immunicum AB as chief technology officer to help build a manufacturing infrastructure for the company’s lead cell-based cancer vaccine. Dr Bertea previously worked at Cellectis SA as head of technical operations Europe and was a member of the company’s executive committee. He has also held senior positions at Novartis and LFB Biotechnologies SAS.
Immunicum announced the appointment on 5 May 2022.
Copyright 2022 Evernow Publishing Ltd